header logo image


Page 640«..1020..639640641642..650660..»

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders – BioSpace

March 25th, 2020 9:47 pm

Board additions will enhance Companys ability to execute on key corporate initiatives

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc.. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments are designed to strengthen the Company as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. The new Board members include Brent Longnecker, Chief Executive Officer of Longnecker & Associates, Jose A. Moreno Toscano, Chief Executive Officer of LFB USA Inc, and William R. (Will) Wilson, Jr., Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co.

This strengthening of the Board of Directors closely follows the Company receiving Fast Track Designation from the Food and Drug Administration (FDA) for its lead drug candidate, raising more than $26 million from institutional investors over the last few months, and licensing a new gene therapy drug candidate for diabetes from the University of Pittsburgh. Also, just yesterday, the Company announced that it strengthened its management team by adding two new senior executives, Catherine Vaczy as Executive Vice President and Chief Strategy Officer, and Michael Redman as Executive Vice President and Chief Operating Officer.

We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company, said Rodney Varner, Chief Executive Officer of Genprex. Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to our develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.

Brent Longnecker has more than 30 years of experience in corporate governance, executive compensation, and risk management consulting for public, private, and non-profit organizations. Mr. Longnecker built one of the countrys leading privately-held executive compensation and corporate governance consultancies, serving both domestic and international markets. Mr. Longnecker has deep expertise in healthcare, energy, real estate, manufacturing, and financial companies, regularly consulting with boards of directors, CEOs, key executives, and advisors in many major industries. He is a prolific author on the subjects of executive compensation and corporate governance.

Jose A. Moreno Toscano brings to the Company over 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations, and general management.

William R. Wilson, Jr. has more than 40 years of experience as an attorney, with legal experience spanning health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, and contractual matters. He previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, as well as Assistant District Attorney for Dallas County, Texas.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso). For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding our possible commercial partnerships and regarding our financial resources. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; our ability to enter into strategic partnerships and the success of those partnerships; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates; and the extent and duration of the current and future economic challenges we may face. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005120/en/

Go here to read the rest:
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders - BioSpace

Read More...

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for…

March 25th, 2020 9:47 pm

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) that it has lifted the hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX.

Since pluripotent stem cells are capable of differentiating into all human cell types potentially genetically modified in any manner, they open the door to a wide array of new therapies, stated Dr. Michael D. West, PhD, founder and CEO of AgeX. This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications.

IMS001 is a formulation of cells derived from AgeX pluripotent stem cells induced to differentiate into mesenchymal cells (hES-MSC) and through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases. IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. ImStem believes this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

The clinical-grade pluripotent stem cell lines from AgeX were the first published GMP-compatible lines ever created, said Xiaofang Wang, MD, PhD, Founder and Chief Technology Officer of ImStem. As such, they have been widely distributed in the scientific community and demonstrated to meet the needs of industry for relatively rapid product development.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC that has undergone IND-enabling, preclinical biodistribution, engraftment, tumorigenicity, toxicology, immunogenicity, and pharmacology studies. IMS001 has demonstrated preclinical immunomodulatory activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs.

Previously published in-vitro data, in collaboration with scientists at the University of Connecticut (UConn) Health, have demonstrated potential advantages of hESC-MSCs in terms of their immunomodulatory effects, as well as the potential to stabilize the blood-brain-barrier (BBB). These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The companys mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology, Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

The rest is here:
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for...

Read More...

Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

March 25th, 2020 9:47 pm

The 85 rating InvestorsObserver gives to Aytu Bioscience Inc (AYTU) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, AYTUs 85 overall rating means the stock scores better than 85 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aytu Bioscience Inc (AYTU) stock is down -16.08% while the S&P 500 has risen 3.65% as of 2:13 PM on Wednesday, Mar 25. AYTU has fallen -$0.32 from the previous closing price of $1.99 on volume of 21,555,025 shares. Over the past year the S&P 500 has fallen -10.00% while AYTU has risen 3.73%. AYTU lost -$1.88 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

Agricultural Biotechnology For Transgenic Crops Market Opportunities and Threats faced by the Key Vendors 2025 – Monroe Scoop

March 25th, 2020 9:46 pm

The Global Agricultural Biotechnology For Transgenic Crops Market is expected to grow from USD 3,179.57 Million in 2018 to USD 9,904.57 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 17.62%.The latest report on Agricultural Biotechnology For Transgenic Crops Market added by Regal Intelligence, focus on market estimates and geographical spectrum of this industry. The report specifies information about Agricultural Biotechnology For Transgenic Crops industry regarding a thorough and detailed assessment of this business.

Further, the Agricultural Biotechnology For Transgenic Crops Market report details important challenges and factors that influence market growth. Further, a detailed comprehensive secondary research was done to collect information on the market segments and sub-segments. Further, primary research was performed to validate the assumptions and findings obtained from secondary research with industry professionals and experts.

Request Free Sample Report at https://www.regalintelligence.com/request-sample/24607

Competitive Landscape:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Agricultural Biotechnology For Transgenic Crops Market including are BASF SE, Bayer AG, Dow AgroSciences LLC, Monsanto Company, Pioneer Hi-Bred International, Inc., Agrilife, Land OLakes, Limagrain, Syngenta AG, and TAKII & CO.,LTD.. On the basis of Type, the Global Agricultural Biotechnology For Transgenic Crops Market is studied across Cisgenic, Multiple Trait Integration, Subgenic, and Transgenic.On the basis of Crop Type, the Global Agricultural Biotechnology For Transgenic Crops Market is studied across Cereals & Grains, Flowers, Fruits & Vegetables, Medicinal Herbs & Spices, and Oilseeds & Pulses.

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this Agricultural Biotechnology For Transgenic Crops Market report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers, and producers etc.

The primary sources from the demand side include Agricultural Biotechnology For Transgenic Crops industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, End-User (product buyers), and related key executives from various key companies and organizations operating in the global Agricultural Biotechnology For Transgenic Crops market.

Primary Types of the industry are

Primary Applications of the industry are

Ask For Table of [emailprotected] https://www.regalintelligence.com/request-toc/24607

This report is based on the synthesis, analysis, and interpretation of information collected on the Agricultural Biotechnology For Transgenic Crops market from various sources. Our analysts have analysed the information & data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the Agricultural Biotechnology For Transgenic Crops Industry.

The following market parameters were considered to estimate market value:

Market Overview

The report includes overviews market introduction, market drivers & influencing factors, restraints & challenges, and potential growth opportunities of Agricultural Biotechnology For Transgenic Crops market. The report consists of market evaluation tools such as Porters five forces, PESTLE Analysis, and value chain analysis.

Key Questions Addressed in the Report:

For more information and discount on this report, reach us at: https://www.regalintelligence.com/check-discount/24607

Thank you for Reading this article.

Read more:
Agricultural Biotechnology For Transgenic Crops Market Opportunities and Threats faced by the Key Vendors 2025 - Monroe Scoop

Read More...

Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 – The InvestChronicle

March 25th, 2020 9:46 pm

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $30.85 to be very precise. The Stock rose vividly during the last session to $37.4 after opening rate of $37 while the lowest price it went was recorded $30.22 before closing at $32.75.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.87% during the 52-week period from high price, and 164.80% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 562686 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 160.44%, having the revenues showcasing 166.91% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.13B, as it employees total of 217 workers.

During the last month, 2 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.80, with a change in the price was noted +16.66. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +115.45% for the period of last 100 days, recording 527,790 in trading volumes.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 29.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.73%. In the last 20 days, the companys Stochastic %K was 19.17% and its Stochastic %D was recorded 29.17%.

Lets take a glance in the erstwhile performances of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 160.44%. The shares increased approximately by 1.54% in the 7-day charts and went down by -34.84% in the period of the last 30 days. Common stock shares were driven by 166.91% during last recorded quarter.

Read more:
Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 - The InvestChronicle

Read More...

What Are The Biggest Industries In Massachusetts? – World Atlas

March 25th, 2020 9:46 pm

Massachusetts is located in the northeastern region of the continental United States. Formally known as the Commonwealth of Massachusetts, the state has a long and storied history as one of America's original thirteen colonies. It was way back in the year 1620 that the first Pilgrims arrived in Plymouth aboard the Mayflower to begin their lives in the New World. Many years later, in 1782, Massachusetts became the sixth state to join the union. All these years later Massachusetts is known as a state which continues to play an integral role in a variety of integral aspects of modern American life especially in regards to the fields of politics, the economy, arts, and culture, as well as national identity.

With a slew of nicknames including the Old Colony State, Baked Bean State, and Puritan State, Massachusetts comprises a total area of 10,565 square miles. The state is currently home to a population of approximately 6,939,373 people and it's capital city, Boston, boosts the highest population rate of any urban center in New England. The leading industries in Massachusetts include biotechnology, maritime trade, engineering, information technology, finance, tourism, as well as higher education.

Biotechnology involves using technological methods in order to modify or alter the biological elements of an organism and/or living system(s). This is done as a means of creating brand new products or processes. Practical examples of biotechnology include the production of various hormones and antibiotics. A number of related scientific disciplines that often work hand in hand with biotechnology include such related fields as biomedical engineering and molecular biology.

Massachusetts' capital city, Boston, is the hub for the biotechnology industry in the state. The city, as well as the neighboring community of Cambridge, are both home to nearly a thousand biotech companies. One of the reasons for this is the large number of universities located in the area. Among the renowned institutes to have facilities in this part of Massachusetts is the Whitehead Institute for Biomedical Research and the Wyss Institute for Biologically Inspired Engineering. Local biotech companies in Massachusetts include ImmunoGen, Boston Scientific, and Vaxess Technologies.

Massachusetts' coastline on the Atlantic Ocean measures approximately 1,500 miles in length. This is the key reason why the state and many of the people who live there have had a long and illustrious relationship with the sea. For many years marine trade has played a vital part in Massachusetts' domestic economy. Local sports in the state have long enabled Americans to trade with communities in such far-flung parts of the world as China and the Caribbean.

For many years, fishing has been an important industry for those residents living on the Atlantic coast of the state. In the nineteenth century, for example, the New England area benefitted considerably from a boom in whaling activities. During this time whales were hunted for food as well as for the valuable oil they provided. Although saltwater fish stocks have been diminishing over the years due to factors such as overfishing and climate change, a large number of Massachusetts residents still make their living off the ocean and activities such as fishing and the harvesting of lobster and Atlantic horseshoe crabs. Among the valuable fish species to be found in the ocean waters off Massachusetts include haddock, monkfish, Atlantic cod, summer flounder, and black sea bass.

Engineering involves the use of scientific methods in order to design and create various structures such as roadways, buildings, tunnels, and bridges. One of Massachusetts' greatest advantages in terms of its engineering industry expertise is the sheer number of engineering colleges and educational facilities located within the state. An educated and highly specialized workforce is a key element in the state's collective success in the field of engineering. Some of these top-rated institutions in Massachusetts include the Massachusetts Institute of Technology (MIT), Franklin W. Olin College of Engineering, Wentworth Institute of Technology as well as a variety of universities including Harvard, Boston, and Tufts.

Commonly referred to as IT the field of information technology involves using computers in order to acquire, archive, and access data. Figures indicate that the northeastern state is home to about 1,708 organizations connected to information technology. Examples of IT companies operating in Massachusetts include Bloomer Health Tech and the Health Data Analytics Institute.

Financial companies make up an important part of the state's economy. As of 2015, it was estimated that approximately a dozen Fortune 500 companies are located in Massachusetts. In 2014 CNBC listed Massachusetts as the 25th best state in the U.S. for business. Financial companies operating in the state include names such as Fidelity Investments, Liberty Mutual Group, and the Massachusetts Mutual Life Insurance Company.

According to statistics from 2015, Massachusetts ranked sixth in terms of the most popular destinations for tourists traveling to the U.S. from other countries. Besides Boston, the state capital and largest city in the state, other communities popular with international visitors include Plymouth, where the Pilgrims landed, and Salem, site of the infamous witch trials. Other well known local attractions include a variety of historical, cultural, and recreational sites such as "Little Women" author Louisa May Alcott's Orchard House in Concord, the Boston Tea Party Ships and Museum, New Bedford Whaling Museum, and Lizzie Borden's house in Fall River.

The state is also home to numerous parks and natural attractions such as the Walden Pond State Reservation in Concord, Wellfleet Bay Wildlife Sanctuary, and Nickerson State Park.

Massachusetts has long been one of the top states in terms of being home to a myriad of educational institutes of higher learning. The state is home to Roxbury Latin School which has the distinction of being the oldest school in continuous operation since it was established in 1645. Massachusetts is also home to the oldest public elementary, high school, and boarding schools as well as the oldest college and women's' college in the nation. The number of higher learning institutions located in Massachusetts totals 121.

Schools of note in Massachusetts include not only Harvard and MIT but also Boston College, Northeastern University, Wellesley College, Amherst College, and the University of Massachusetts.

Read more:
What Are The Biggest Industries In Massachusetts? - World Atlas

Read More...

Global Epigenetic Market Expected to Grow with a CAGR of 14%, 2019-2024 – ResearchAndMarkets.com – Benzinga

March 25th, 2020 9:46 pm

The "Epigenetic Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The future of the epigenetic market looks promising with opportunities in the pharmaceutical and biotechnology industries. The global epigenetic market is expected to grow with a CAGR of 14% from 2019 to 2024. The major growth drivers for this market are declining sequencing costs and time, increasing research activities and availability of government funding, and rising cancer prevalence.

A report of more than 150 pages is developed to help in your business decisions. To learn the scope of, benefits, companies researched and other details of the epigenetic market, then read this report.

Some of the features of Global Epigenetic Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global epigenetic market by product, application, technology, and region?

Q.2 Which segments will grow at a faster pace and why?

Q.3 Which regions will grow at a faster pace and why?

Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the epigenetic market?

Q.5 What are the business risks and threats to the epigenetic market?

Q.6 What are emerging trends in this epigenetic market and the reasons behind them?

Q.7 What are some changing demands of customers in the epigenetic market?

Q.8 What are the new developments in the epigenetic market? Which companies are leading these developments?

Q.9 Who are the major players in this epigenetic market? What strategic initiatives are being implemented by key players for business growth?

Q.10 What are some of the competitive products and processes in this epigenetic area and how big of a threat do they pose for loss of market share via material or product substitution?

Q.11 What M & A activities have taken place in the last 5 years in epigenetic market?

Key Topics Covered:

1. Executive Summary

2. Market Background and Classifications

2.1: Introduction, Background, and Classifications

2.2: Supply Chain

2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

3.1: Macroeconomic Trends and Forecast

3.2: Global Epigenetic Market: Trends and Forecast

3.3: Global Epigenetic Market by Product Type

3.3.1: Enzymes

3.3.2: Kits

3.3.3: Reagents

3.3.4: Bioinformatics Tools

3.4: Global Epigenetic Market by Application

3.4.1: Oncology

3.4.2: Non Oncology

3.5: Global Epigenetic Market by End Use Industry

3.5.1: Pharmaceutical

3.5.2: Biotechnology

3.5.3: Others

3.6: Global Epigenetic Market by Technology

3.6.1: DNA Methylation

3.6.2: Histone Methylation

3.6.3: Histone Acetylation

3.6.4: Large Noncoding RNA

3.6.5: MicroRNA Modification

3.6.6: Chromatin structures

3.6.7: Others

4. Market Trends and Forecast Analysis by Region

4.1: Global Epigenetic Market by Region

4.2: North American Epigenetic Market

4.2.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.2.2: Market by Application: Oncology and Non Oncology

4.2.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.2.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.3: European Epigenetic Market

4.3.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.3.2: Market by Application: Oncology and Non Oncology

4.3.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.3.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.4: APAC Epigenetic Market

4.4.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.4.2: Market by Application: Oncology and Non Oncology

4.4.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.4.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.5: Row Epigenetic Market

4.5.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.5.2: Market by Application: Oncology and Non Oncology

4.5.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.5.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis

5.2: Market Share Analysis

5.3: Operational Integration

5.4: Geographical Reach

5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis

6.1.1: Growth Opportunities for Global Epigenetic Market by Product Type

6.1.2: Growth Opportunities for Global Epigenetic Market by Application

6.1.3: Growth Opportunities for Global Market by End Use Industry

6.1.4: Growth Opportunities for Global Market by Technology

6.1.5: Growth Opportunities for Global Epigenetic Market by Region

6.2: Emerging Trends in Global Epigenetic Market

6.3: Strategic Analysis

6.3.1: New Product Development

6.3.2: Capacity Expansion of Global Epigenetic Market

6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players

7.1: Illumina

7.2: Thermo Fisher Scientific

7.3: Merck Millipore

7.4: Abcam

7.5: Active Motif

7.6: Bio-Rad

See original here:
Global Epigenetic Market Expected to Grow with a CAGR of 14%, 2019-2024 - ResearchAndMarkets.com - Benzinga

Read More...

Industry Breakdown: Where Does Vir Biotechnology Inc (VIR) Stock Fall in the Biotechnology Field? – InvestorsObserver

March 25th, 2020 9:46 pm

The 31 rating InvestorsObserver gives to Vir Biotechnology Inc (VIR) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 12 percent of stocks in the Biotechnology industry, VIRs 31 overall rating means the stock scores better than 31 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 31 means the stock is more attractive than 31 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Vir Biotechnology Inc (VIR) stock is trading at $36.76 as of 12:45 PM on Monday, Mar 23, a drop of -$3.00, or -7.55% from the previous closing price of $39.76. The stock has traded between $36.15 and $39.94 so far today. Volume today is low. So far 218,746 shares have traded compared to average volume of 1,059,947 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original here:
Industry Breakdown: Where Does Vir Biotechnology Inc (VIR) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2…

March 25th, 2020 9:46 pm

MIRAMAR, Fla. , March 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the companys proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerexImmuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation. Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.

Generex President & CEO Joseph Moscato said, Generex wants to let everyone know that we are ready and willing to partner on our coronavirus vaccine development program with government health agencies across the globe. Based on our discussions with numerous people throughout the U.S. government and international health agencies, it is clear that additional information is needed by the authorities about the potential to rapidly create a vaccine using our Ii-Key technology to fight the COVID-19 pandemic. Generex has long standing experience developing Ii-Key peptide vaccines for infectious diseases and cancer, so wehave developeda strategy to design, screen and identify vaccine peptides to any novel pathogenic virus to initiate human clinical trials in 3 to 5 months depending on regulatory agency requirements.We have vaccinated over 300 people with Ii-Key vaccines to demonstrate their safety and their ability to activate the immune response against peptide epitopes. As a public service to expedite the review of the Ii-Key vaccine technology by interested parties, we are providing a summary of safety on our Ii-Key development program from both published peer-reviewed literature as well as from our clinical investigator brochures on our website at Generex.com.

Mr. Moscato continued, We ask that governments, health ministries, and large pharmaceutical companies please take note of the potential for Ii-Key peptide vaccines to slow the spread of the SARS-CoV-2 virus. We are advancing the coronavirus project with our partners in China, and we are available to partner with other countries to develop and commercialize our Ii-Key-SARS-2 vaccine. To date we have been in touch with the VA, BARDA, and HHS in the United States, and we are in communication with the Canadian Ministry of Health, as well as with authorities in Greece, England, Saudi Arabia, Iceland, Indonesia, Philippines, Italy, and Romania for licensing our Ii-Key-SARS-2 peptide vaccines as well as new, patented immunotherapy technology that will provide those countries with co-ownership of the Intellectual Property in their territories. We have engaged Morris L. Reid of Mercury LLC (http://mercuryllc.com) to advise the company on international licensing strategy.

Defeating coronavirus requires a public/private partnership, stated Mr. Reid, Partner at Mercury. Government cannot do it alone and must collaborate with the private sector in order to bring the best innovation to the table.

Mr. Moscatoadded his thoughts on peptide vaccines, stating, We know one thing about vaccines and the immune response, and that is our immune system recognizes antigenic epitopes, which are made of amino acid peptides, and mounts a multicellular response to protect the body from invaders like viruses or cancer. Whether you use attenuated or killed viruses or recombinant proteins, peptides are and have been the primary pathway to create vaccines. Peptide vaccines, especially when linked with the Ii-Key, are proven to generate an immune response, and we have demonstrated the safety of various Ii-Key peptide vaccines in animal models and human clinical trials. Over the years, Generex has developed a proven process to generate rapid peptide vaccines using the latest computational algorithms to select the best peptides to create an immune response, and we can link these peptide epitopes to the Ii-key for a very powerful solution that is cost effective and easy to manufacture on a large scale. Every country in the world needs our Ii-key technology in their national health arsenal not only for this coronavirus, but also to respond to future SARS virus mutations and other potential pandemic viruses that have been on the rise the last 20 years.

Story continues

For further information from government or corporate inquiries please email:covid-19@nugenerexio.com

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Mercks Keytruda) for the treatment of triple negative breast cancer.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

Tel: 1-800-391-6755 Extension 222 Email: investor@generex.com

Excerpt from:
Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2...

Read More...

PhD Fellow within Food Science in the Area of Food of Plant Origin job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY -NTNU | 201301 – Times…

March 25th, 2020 9:46 pm

About the position

We have a vacancy for a PhD fellow within Food Science in the area of foods of plant origin.

The PhD position is available within the Food Science division at the Department of Biotechnology and Food Science. The project will be related to the research about bioactive compounds that are could be found in plants with emphasis on the utilization of by-products.

The overall aim of the PhD project will be to increase the knowledge from the fields of bioactive compounds found in red vegetables either in their edible parts or by-products from their processing. Phytonutrients that are responsible for their red color have powerful health benefits but are prone to degradation during processing and storage. The PhD candidate will work with various methods of extraction and processing technologies that aim to protect chemical substances like betalains, carotenoids, anthocyanins, polyphenols, flavonoids, saponins.

You will reportto Associate Professor Marcin A. Kurek

Duties of the position

Required selection criteria

The PhD-position's main objective is to qualify for work in research positions. The qualification requirement is completion of a masters degree or second degree (equivalent to 120 credits) with a strong academic background in food science, food processing, food technology, food engineering, food chemistry, food microbiology, biotechnology, vegetable biotechnology or equivalent education with a grade of B or better in terms of NTNUs grading scale. Applicants with no letter grades from previous studies must have an equally good academic foundation. Applicants who are unable to meet these criteria may be considered only if they can document that they are particularly suitable candidates for education leading to a PhD degree.

The appointment is to be made in accordance with the regulations in force concerning State Employees and Civil Servants and national guidelines for appointment as PhD, post doctor and research assistant.

Other qualifications

Personal characteristics

In the evaluation of which candidate is best qualified, emphasis will be placed on education, experience and personal suitability.

We offer

Salary and conditions

PhD candidates are remunerated in code 1017, and are normally remunerated at gross from NOK 479 600 per annum before tax, depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The period of employment is 3 years with the possibility of 1 year extension with teaching duties.

Appointment to a PhD position requires that you are admitted to the PhD programme in Biotechnology (https://www.ntnu.edu/studies/phbiot) within three months of employment, and that you participate in an organized PhD programme during the employment period.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite you can be present at and accessible to the institution on a daily basis.

About the application

Publications and other scientific work must follow the application. Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

General information

A good work environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background.

The city of Trondheim is a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

NTNU is committed to following evaluation criteria for research quality according to The San Francisco Declaration on Research Assessment - DORA.

As an employeeatNTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Information Act (Offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact Associate Professor Marcin A. Kurek, email: marcin.kurek@ntnu.no

Please submit your application electronically via jobbnorge.no with your CV, diplomas and certificates. Applications submitted elsewhere will not be considered. Diploma Supplement is required to attach for European Master Diplomas outside Norway. Chinese applicants are required to provide confirmation of Master Diploma from China Credentials Verification (CHSI).

If you are invited for interview you must include certified copies of transcripts and reference letters. Together with the application we request up to one page Personal motivation letter for the position.

Please refer to the application number NV-41/20 when applying.

Application deadline: 20.04.2020

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

Department of Biotechnology and Food Science

Our activities contribute to increased exploitation of existing and new ingredients for sustainable food production as well as next-generation energy solutions and medical technology. We educate graduates for a wide range of careers in industry, public administration and academia. The Department of Biotechnology and Food Science is one of eight departments in the Faculty of Natural Sciences.

Deadline 20th April 2020Employer NTNU - Norwegian University of Science and TechnologyMunicipality TrondheimScope FulltimeDuration TemporaryPlace of service Trondheim

Originally posted here:
PhD Fellow within Food Science in the Area of Food of Plant Origin job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY -NTNU | 201301 - Times...

Read More...

How the Pandemic Will End – The Atlantic

March 25th, 2020 9:45 pm

Editors Note: The Atlantic is making vital coverage of the coronavirus available to all readers. Find the collection here.

Three months ago, no one knew that SARS-CoV-2 existed. Now the virus has spread to almost every country, infecting at least 446,000 people whom we know about, and many more whom we do not. It has crashed economies and broken health-care systems, filled hospitals and emptied public spaces. It has separated people from their workplaces and their friends. It has disrupted modern society on a scale that most living people have never witnessed. Soon, most everyone in the United States will know someone who has been infected. Like World War II or the 9/11 attacks, this pandemic has already imprinted itself upon the nations psyche.

A global pandemic of this scale was inevitable. In recent years, hundreds of health experts have written books, white papers, and op-eds warning of the possibility. Bill Gates has been telling anyone who would listen, including the 18 million viewers of his TED Talk. In 2018, I wrote a story for The Atlantic arguing that America was not ready for the pandemic that would eventually come. In October, the Johns Hopkins Center for Health Security war-gamed what might happen if a new coronavirus swept the globe. And then one did. Hypotheticals became reality. What if? became Now what?

So, now what? In the late hours of last Wednesday, which now feels like the distant past, I was talking about the pandemic with a pregnant friend who was days away from her due date. We realized that her child might be one of the first of a new cohort who are born into a society profoundly altered by COVID-19. We decided to call them Generation C.

As well see, Gen Cs lives will be shaped by the choices made in the coming weeks, and by the losses we suffer as a result. But first, a brief reckoning. On the Global Health Security Index, a report card that grades every country on its pandemic preparedness, the United States has a score of 83.5the worlds highest. Rich, strong, developed, America is supposed to be the readiest of nations. That illusion has been shattered. Despite months of advance warning as the virus spread in other countries, when America was finally tested by COVID-19, it failed.

Anne Applebaum: The coronavirus called Americas bluff

No matter what, a virus [like SARS-CoV-2] was going to test the resilience of even the most well-equipped health systems, says Nahid Bhadelia, an infectious-diseases physician at the Boston University School of Medicine. More transmissible and fatal than seasonal influenza, the new coronavirus is also stealthier, spreading from one host to another for several days before triggering obvious symptoms. To contain such a pathogen, nations must develop a test and use it to identify infected people, isolate them, and trace those theyve had contact with. That is what South Korea, Singapore, and Hong Kong did to tremendous effect. It is what the United States did not.

As my colleagues Alexis Madrigal and Robinson Meyer have reported, the Centers for Disease Control and Prevention developed and distributed a faulty test in February. Independent labs created alternatives, but were mired in bureaucracy from the FDA. In a crucial month when the American caseload shot into the tens of thousands, only hundreds of people were tested. That a biomedical powerhouse like the U.S. should so thoroughly fail to create a very simple diagnostic test was, quite literally, unimaginable. Im not aware of any simulations that I or others have run where we [considered] a failure of testing, says Alexandra Phelan of Georgetown University, who works on legal and policy issues related to infectious diseases.

The testing fiasco was the original sin of Americas pandemic failure, the single flaw that undermined every other countermeasure. If the country could have accurately tracked the spread of the virus, hospitals could have executed their pandemic plans, girding themselves by allocating treatment rooms, ordering extra supplies, tagging in personnel, or assigning specific facilities to deal with COVID-19 cases. None of that happened. Instead, a health-care system that already runs close to full capacity, and that was already challenged by a severe flu season, was suddenly faced with a virus that had been left to spread, untracked, through communities around the country. Overstretched hospitals became overwhelmed. Basic protective equipment, such as masks, gowns, and gloves, began to run out. Beds will soon follow, as will the ventilators that provide oxygen to patients whose lungs are besieged by the virus.

Read: The people ignoring social distancing

With little room to surge during a crisis, Americas health-care system operates on the assumption that unaffected states can help beleaguered ones in an emergency. That ethic works for localized disasters such as hurricanes or wildfires, but not for a pandemic that is now in all 50 states. Cooperation has given way to competition; some worried hospitals have bought out large quantities of supplies, in the way that panicked consumers have bought out toilet paper.

Partly, thats because the White House is a ghost town of scientific expertise. A pandemic-preparedness office that was part of the National Security Council was dissolved in 2018. On January 28, Luciana Borio, who was part of that team, urged the government to act now to prevent an American epidemic, and specifically to work with the private sector to develop fast, easy diagnostic tests. But with the office shuttered, those warnings were published in The Wall Street Journal, rather than spoken into the presidents ear. Instead of springing into action, America sat idle.

Derek Thompson: America is acting like a failed state

Rudderless, blindsided, lethargic, and uncoordinated, America has mishandled the COVID-19 crisis to a substantially worse degree than what every health expert Ive spoken with had feared. Much worse, said Ron Klain, who coordinated the U.S. response to the West African Ebola outbreak in 2014. Beyond any expectations we had, said Lauren Sauer, who works on disaster preparedness at Johns Hopkins Medicine. As an American, Im horrified, said Seth Berkley, who heads Gavi, the Vaccine Alliance. The U.S. may end up with the worst outbreak in the industrialized world.

Having fallen behind, it will be difficultbut not impossiblefor the United States to catch up. To an extent, the near-term future is set because COVID-19 is a slow and long illness. People who were infected several days ago will only start showing symptoms now, even if they isolated themselves in the meantime. Some of those people will enter intensive-care units in early April. As of last weekend, the nation had 17,000 confirmed cases, but the actual number was probably somewhere between 60,000 and 245,000. Numbers are now starting to rise exponentially: As of Wednesday morning, the official case count was 54,000, and the actual case count is unknown. Health-care workers are already seeing worrying signs: dwindling equipment, growing numbers of patients, and doctors and nurses who are themselves becoming infected.

Italy and Spain offer grim warnings about the future. Hospitals are out of room, supplies, and staff. Unable to treat or save everyone, doctors have been forced into the unthinkable: rationing care to patients who are most likely to survive, while letting others die. The U.S. has fewer hospital beds per capita than Italy. A study released by a team at Imperial College London concluded that if the pandemic is left unchecked, those beds will all be full by late April. By the end of June, for every available critical-care bed, there will be roughly 15 COVID-19 patients in need of one. By the end of the summer, the pandemic will have directly killed 2.2 million Americans, notwithstanding those who will indirectly die as hospitals are unable to care for the usual slew of heart attacks, strokes, and car accidents. This is the worst-case scenario. To avert it, four things need to happenand quickly.

Read: All the presidents lies about the coronavirus

The first and most important is to rapidly produce masks, gloves, and other personal protective equipment. If health-care workers cant stay healthy, the rest of the response will collapse. In some places, stockpiles are already so low that doctors are reusing masks between patients, calling for donations from the public, or sewing their own homemade alternatives. These shortages are happening because medical supplies are made-to-order and depend on byzantine international supply chains that are currently straining and snapping. Hubei province in China, the epicenter of the pandemic, was also a manufacturing center of medical masks.

In the U.S., the Strategic National Stockpilea national larder of medical equipmentis already being deployed, especially to the hardest-hit states. The stockpile is not inexhaustible, but it can buy some time. Donald Trump could use that time to invoke the Defense Production Act, launching a wartime effort in which American manufacturers switch to making medical equipment. But after invoking the act last Wednesday, Trump has failed to actually use it, reportedly due to lobbying from the U.S. Chamber of Commerce and heads of major corporations.

Some manufacturers are already rising to the challenge, but their efforts are piecemeal and unevenly distributed. One day, well wake up to a story of doctors in City X who are operating with bandanas, and a closet in City Y with masks piled into it, says Ali Khan, the dean of public health at the University of Nebraska Medical Center. A massive logistics and supply-chain operation [is] now needed across the country, says Thomas Inglesby of Johns Hopkins Bloomberg School of Public Health. That cant be managed by small and inexperienced teams scattered throughout the White House. The solution, he says, is to tag in the Defense Logistics Agencya 26,000-person group that prepares the U.S. military for overseas operations and that has assisted in past public-health crises, including the 2014 Ebola outbreak.

This agency can also coordinate the second pressing need: a massive rollout of COVID-19 tests. Those tests have been slow to arrive because of five separate shortages: of masks to protect people administering the tests; of nasopharyngeal swabs for collecting viral samples; of extraction kits for pulling the viruss genetic material out of the samples; of chemical reagents that are part of those kits; and of trained people who can give the tests. Many of these shortages are, again, due to strained supply chains. The U.S. relies on three manufacturers for extraction reagents, providing redundancy in case any of them failsbut all of them failed in the face of unprecedented global demand. Meanwhile, Lombardy, Italy, the hardest-hit place in Europe, houses one of the largest manufacturers of nasopharyngeal swabs.

Read: Why the coronavirus has been so successful

Some shortages are being addressed. The FDA is now moving quickly to approve tests developed by private labs. At least one can deliver results in less than an hour, potentially allowing doctors to know if the patient in front of them has COVID-19. The country is adding capacity on a daily basis, says Kelly Wroblewski of the Association of Public Health Laboratories.

On March 6, Trump said that anyone who wants a test can get a test. That was (and still is) untrue, and his own officials were quick to correct him. Regardless, anxious people still flooded into hospitals, seeking tests that did not exist. People wanted to be tested even if they werent symptomatic, or if they sat next to someone with a cough, says Saskia Popescu of George Mason University, who works to prepare hospitals for pandemics. Others just had colds, but doctors still had to use masks to examine them, burning through their already dwindling supplies. It really stressed the health-care system, Popescu says. Even now, as capacity expands, tests must be used carefully. The first priority, says Marc Lipsitch of Harvard, is to test health-care workers and hospitalized patients, allowing hospitals to quell any ongoing fires. Only later, once the immediate crisis is slowing, should tests be deployed in a more widespread way. This isnt just going to be: Lets get the tests out there! Inglesby says.

These measures will take time, during which the pandemic will either accelerate beyond the capacity of the health system or slow to containable levels. Its courseand the nations fatenow depends on the third need, which is social distancing. Think of it this way: There are now only two groups of Americans. Group A includes everyone involved in the medical response, whether thats treating patients, running tests, or manufacturing supplies. Group B includes everyone else, and their job is to buy Group A more time. Group B must now flatten the curve by physically isolating themselves from other people to cut off chains of transmission. Given the slow fuse of COVID-19, to forestall the future collapse of the health-care system, these seemingly drastic steps must be taken immediately, before they feel proportionate, and they must continue for several weeks.

Juliette Kayyem: The crisis could last 18 months. Be prepared.

Persuading a country to voluntarily stay at home is not easy, and without clear guidelines from the White House, mayors, governors, and business owners have been forced to take their own steps. Some states have banned large gatherings or closed schools and restaurants. At least 21 have now instituted some form of mandatory quarantine, compelling people to stay at home. And yet many citizens continue to crowd into public spaces.

In these moments, when the good of all hinges on the sacrifices of many, clear coordination mattersthe fourth urgent need. The importance of social distancing must be impressed upon a public who must also be reassured and informed. Instead, Trump has repeatedly played down the problem, telling America that we have it very well under control when we do not, and that cases were going to be down to close to zero when they were rising. In some cases, as with his claims about ubiquitous testing, his misleading gaffes have deepened the crisis. He has even touted unproven medications.

Away from the White House press room, Trump has apparently been listening to Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. Fauci has advised every president since Ronald Reagan on new epidemics, and now sits on the COVID-19 task force that meets with Trump roughly every other day. Hes got his own style, lets leave it at that, Fauci told me, but any kind of recommendation that I have made thus far, the substance of it, he has listened to everything.

Read: Grocery stores are the coronavirus tipping point

But Trump already seems to be wavering. In recent days, he has signaled that he is prepared to backtrack on social-distancing policies in a bid to protect the economy. Pundits and business leaders have used similar rhetoric, arguing that high-risk people, such as the elderly, could be protected while lower-risk people are allowed to go back to work. Such thinking is seductive, but flawed. It overestimates our ability to assess a persons risk, and to somehow wall off the high-risk people from the rest of society. It underestimates how badly the virus can hit low-risk groups, and how thoroughly hospitals will be overwhelmed if even just younger demographics are falling sick.

A recent analysis from the University of Pennsylvania estimated that even if social-distancing measures can reduce infection rates by 95 percent, 960,000 Americans will still need intensive care. There are only about 180,000 ventilators in the U.S. and, more pertinently, only enough respiratory therapists and critical-care staff to safely look after 100,000 ventilated patients. Abandoning social distancing would be foolish. Abandoning it now, when tests and protective equipment are still scarce, would be catastrophic.

Read: Americas hospitals have never experienced anything like this

If Trump stays the course, if Americans adhere to social distancing, if testing can be rolled out, and if enough masks can be produced, there is a chance that the country can still avert the worst predictions about COVID-19, and at least temporarily bring the pandemic under control. No one knows how long that will take, but it wont be quick. It could be anywhere from four to six weeks to up to three months, Fauci said, but I dont have great confidence in that range.

Even a perfect response wont end the pandemic. As long as the virus persists somewhere, theres a chance that one infected traveler will reignite fresh sparks in countries that have already extinguished their fires. This is already happening in China, Singapore, and other Asian countries that briefly seemed to have the virus under control. Under these conditions, there are three possible endgames: one thats very unlikely, one thats very dangerous, and one thats very long.

The first is that every nation manages to simultaneously bring the virus to heel, as with the original SARS in 2003. Given how widespread the coronavirus pandemic is, and how badly many countries are faring, the odds of worldwide synchronous control seem vanishingly small.

The second is that the virus does what past flu pandemics have done: It burns through the world and leaves behind enough immune survivors that it eventually struggles to find viable hosts. This herd immunity scenario would be quick, and thus tempting. But it would also come at a terrible cost: SARS-CoV-2 is more transmissible and fatal than the flu, and it would likely leave behind many millions of corpses and a trail of devastated health systems. The United Kingdom initially seemed to consider this herd-immunity strategy, before backtracking when models revealed the dire consequences. The U.S. now seems to be considering it too.

Read: What will you do if you start coughing?

The third scenario is that the world plays a protracted game of whack-a-mole with the virus, stamping out outbreaks here and there until a vaccine can be produced. This is the best option, but also the longest and most complicated.

It depends, for a start, on making a vaccine. If this were a flu pandemic, that would be easier. The world is experienced at making flu vaccines and does so every year. But there are no existing vaccines for coronavirusesuntil now, these viruses seemed to cause diseases that were mild or rareso researchers must start from scratch. The first steps have been impressively quick. Last Monday, a possible vaccine created by Moderna and the National Institutes of Health went into early clinical testing. That marks a 63-day gap between scientists sequencing the viruss genes for the first time and doctors injecting a vaccine candidate into a persons arm. Its overwhelmingly the world record, Fauci said.

But its also the fastest step among many subsequent slow ones. The initial trial will simply tell researchers if the vaccine seems safe, and if it can actually mobilize the immune system. Researchers will then need to check that it actually prevents infection from SARS-CoV-2. Theyll need to do animal tests and large-scale trials to ensure that the vaccine doesnt cause severe side effects. Theyll need to work out what dose is required, how many shots people need, if the vaccine works in elderly people, and if it requires other chemicals to boost its effectiveness.

Even if it works, they dont have an easy way to manufacture it at a massive scale, said Seth Berkley of Gavi. Thats because Moderna is using a new approach to vaccination. Existing vaccines work by providing the body with inactivated or fragmented viruses, allowing the immune system to prep its defenses ahead of time. By contrast, Modernas vaccine comprises a sliver of SARS-CoV-2s genetic materialits RNA. The idea is that the body can use this sliver to build its own viral fragments, which would then form the basis of the immune systems preparations. This approach works in animals, but is unproven in humans. By contrast, French scientists are trying to modify the existing measles vaccine using fragments of the new coronavirus. The advantage of that is that if we needed hundreds of doses tomorrow, a lot of plants in the world know how to do it, Berkley said. No matter which strategy is faster, Berkley and others estimate that it will take 12 to 18 months to develop a proven vaccine, and then longer still to make it, ship it, and inject it into peoples arms.

Read: COVID-19 vaccines are coming, but theyre not what you think

Its likely, then, that the new coronavirus will be a lingering part of American life for at least a year, if not much longer. If the current round of social-distancing measures works, the pandemic may ebb enough for things to return to a semblance of normalcy. Offices could fill and bars could bustle. Schools could reopen and friends could reunite. But as the status quo returns, so too will the virus. This doesnt mean that society must be on continuous lockdown until 2022. But we need to be prepared to do multiple periods of social distancing, says Stephen Kissler of Harvard.

Much about the coming years, including the frequency, duration, and timing of social upheavals, depends on two properties of the virus, both of which are currently unknown. First: seasonality. Coronaviruses tend to be winter infections that wane or disappear in the summer. That may also be true for SARS-CoV-2, but seasonal variations might not sufficiently slow the virus when it has so many immunologically naive hosts to infect. Much of the world is waiting anxiously to see whatif anythingthe summer does to transmission in the Northern Hemisphere, says Maia Majumder of Harvard Medical School and Boston Childrens Hospital.

Second: duration of immunity. When people are infected by the milder human coronaviruses that cause cold-like symptoms, they remain immune for less than a year. By contrast, the few who were infected by the original SARS virus, which was far more severe, stayed immune for much longer. Assuming that SARS-CoV-2 lies somewhere in the middle, people who recover from their encounters might be protected for a couple of years. To confirm that, scientists will need to develop accurate serological tests, which look for the antibodies that confer immunity. Theyll also need to confirm that such antibodies actually stop people from catching or spreading the virus. If so, immune citizens can return to work, care for the vulnerable, and anchor the economy during bouts of social distancing.

Scientists can use the periods between those bouts to develop antiviral drugsalthough such drugs are rarely panaceas, and come with possible side effects and the risk of resistance. Hospitals can stockpile the necessary supplies. Testing kits can be widely distributed to catch the viruss return as quickly as possible. Theres no reason that the U.S. should let SARS-CoV-2 catch it unawares again, and thus no reason that social-distancing measures need to be deployed as broadly and heavy-handedly as they now must be. As Aaron E. Carroll and Ashish Jha recently wrote, We can keep schools and businesses open as much as possible, closing them quickly when suppression fails, then opening them back up again once the infected are identified and isolated. Instead of playing defense, we could play more offense.

Whether through accumulating herd immunity or the long-awaited arrival of a vaccine, the virus will find spreading explosively more and more difficult. Its unlikely to disappear entirely. The vaccine may need to be updated as the virus changes, and people may need to get revaccinated on a regular basis, as they currently do for the flu. Models suggest that the virus might simmer around the world, triggering epidemics every few years or so. But my hope and expectation is that the severity would decline, and there would be less societal upheaval, Kissler says. In this future, COVID-19 may become like the flu is todaya recurring scourge of winter. Perhaps it will eventually become so mundane that even though a vaccine exists, large swaths of Gen C wont bother getting it, forgetting how dramatically their world was molded by its absence.

The cost of reaching that point, with as few deaths as possible, will be enormous. As my colleague Annie Lowrey wrote, the economy is experiencing a shock more sudden and severe than anyone alive has ever experienced. About one in five people in the United States have lost working hours or jobs. Hotels are empty. Airlines are grounding flights. Restaurants and other small businesses are closing. Inequalities will widen: People with low incomes will be hardest-hit by social-distancing measures, and most likely to have the chronic health conditions that increase their risk of severe infections. Diseases have destabilized cities and societies many times over, but it hasnt happened in this country in a very long time, or to quite the extent that were seeing now, says Elena Conis, a historian of medicine at UC Berkeley. Were far more urban and metropolitan. We have more people traveling great distances and living far from family and work.

After infections begin ebbing, a secondary pandemic of mental-health problems will follow. At a moment of profound dread and uncertainty, people are being cut off from soothing human contact. Hugs, handshakes, and other social rituals are now tinged with danger. People with anxiety or obsessive-compulsive disorder are struggling. Elderly people, who are already excluded from much of public life, are being asked to distance themselves even further, deepening their loneliness. Asian people are suffering racist insults, fueled by a president who insists on labeling the new coronavirus the Chinese virus. Incidents of domestic violence and child abuse are likely to spike as people are forced to stay in unsafe homes. Children, whose bodies are mostly spared by the virus, may endure mental trauma that stays with them into adulthood.

Read: The kids arent all right

After the pandemic, people who recover from COVID-19 might be shunned and stigmatized, as were survivors of Ebola, SARS, and HIV. Health-care workers will take time to heal: One to two years after SARS hit Toronto, people who dealt with the outbreak were still less productive and more likely to be experiencing burnout and post-traumatic stress. People who went through long bouts of quarantine will carry the scars of their experience. My colleagues in Wuhan note that some people there now refuse to leave their homes and have developed agoraphobia, says Steven Taylor of the University of British Columbia, who wrote The Psychology of Pandemics.

But there is also the potential for a much better world after we get through this trauma, says Richard Danzig of the Center for a New American Security. Already, communities are finding new ways of coming together, even as they must stay apart. Attitudes to health may also change for the better. The rise of HIV and AIDS completely changed sexual behavior among young people who were coming into sexual maturity at the height of the epidemic, Conis says. The use of condoms became normalized. Testing for STDs became mainstream. Similarly, washing your hands for 20 seconds, a habit that has historically been hard to enshrine even in hospitals, may be one of those behaviors that we become so accustomed to in the course of this outbreak that we dont think about them, Conis adds.

Pandemics can also catalyze social change. People, businesses, and institutions have been remarkably quick to adopt or call for practices that they might once have dragged their heels on, including working from home, conference-calling to accommodate people with disabilities, proper sick leave, and flexible child-care arrangements. This is the first time in my lifetime that Ive heard someone say, Oh, if youre sick, stay home, says Adia Benton, an anthropologist at Northwestern University. Perhaps the nation will learn that preparedness isnt just about masks, vaccines, and tests, but also about fair labor policies and a stable and equal health-care system. Perhaps it will appreciate that health-care workers and public-health specialists compose Americas social immune system, and that this system has been suppressed.

Aspects of Americas identity may need rethinking after COVID-19. Many of the countrys values have seemed to work against it during the pandemic. Its individualism, exceptionalism, and tendency to equate doing whatever you want with an act of resistance meant that when it came time to save lives and stay indoors, some people flocked to bars and clubs. Having internalized years of anti-terrorism messaging following 9/11, Americans resolved to not live in fear. But SARS-CoV-2 has no interest in their terror, only their cells.

Years of isolationist rhetoric had consequences too. Citizens who saw China as a distant, different place, where bats are edible and authoritarianism is acceptable, failed to consider that they would be next or that they wouldnt be ready. (Chinas response to this crisis had its own problems, but thats for another time.) People believed the rhetoric that containment would work, says Wendy Parmet, who studies law and public health at Northeastern University. We keep them out, and well be okay. When you have a body politic that buys into these ideas of isolationism and ethnonationalism, youre especially vulnerable when a pandemic hits.

Graeme Wood: The Chinese virus is a test. Dont fail it.

Veterans of past epidemics have long warned that American society is trapped in a cycle of panic and neglect. After every crisisanthrax, SARS, flu, Ebolaattention is paid and investments are made. But after short periods of peacetime, memories fade and budgets dwindle. This trend transcends red and blue administrations. When a new normal sets in, the abnormal once again becomes unimaginable. But there is reason to think that COVID-19 might be a disaster that leads to more radical and lasting change.

The other major epidemics of recent decades either barely affected the U.S. (SARS, MERS, Ebola), were milder than expected (H1N1 flu in 2009), or were mostly limited to specific groups of people (Zika, HIV). The COVID-19 pandemic, by contrast, is affecting everyone directly, changing the nature of their everyday life. That distinguishes it not only from other diseases, but also from the other systemic challenges of our time. When an administration prevaricates on climate change, the effects wont be felt for years, and even then will be hard to parse. Its different when a president says that everyone can get a test, and one day later, everyone cannot. Pandemics are democratizing experiences. People whose privilege and power would normally shield them from a crisis are facing quarantines, testing positive, and losing loved ones. Senators are falling sick. The consequences of defunding public-health agencies, losing expertise, and stretching hospitals are no longer manifesting as angry opinion pieces, but as faltering lungs.

After 9/11, the world focused on counterterrorism. After COVID-19, attention may shift to public health. Expect to see a spike in funding for virology and vaccinology, a surge in students applying to public-health programs, and more domestic production of medical supplies. Expect pandemics to top the agenda at the United Nations General Assembly. Anthony Fauci is now a household name. Regular people who think easily about what a policewoman or firefighter does finally get what an epidemiologist does, says Monica Schoch-Spana, a medical anthropologist at the Johns Hopkins Center for Health Security.

Such changes, in themselves, might protect the world from the next inevitable disease. The countries that had lived through SARS had a public consciousness about this that allowed them to leap into action, said Ron Klain, the former Ebola czar. The most commonly uttered sentence in America at the moment is, Ive never seen something like this before. That wasnt a sentence anyone in Hong Kong uttered. For the U.S., and for the world, its abundantly, viscerally clear what a pandemic can do.

The lessons that America draws from this experience are hard to predict, especially at a time when online algorithms and partisan broadcasters only serve news that aligns with their audiences preconceptions. Such dynamics will be pivotal in the coming months, says Ilan Goldenberg, a foreign-policy expert at the Center for a New American Security. The transitions after World War II or 9/11 were not about a bunch of new ideas, he says. The ideas are out there, but the debates will be more acute over the next few months because of the fluidity of the moment and willingness of the American public to accept big, massive changes.

One could easily conceive of a world in which most of the nation believes that America defeated COVID-19. Despite his many lapses, Trumps approval rating has surged. Imagine that he succeeds in diverting blame for the crisis to China, casting it as the villain and America as the resilient hero. During the second term of his presidency, the U.S. turns further inward and pulls out of NATO and other international alliances, builds actual and figurative walls, and disinvests in other nations. As Gen C grows up, foreign plagues replace communists and terrorists as the new generational threat.

One could also envisage a future in which America learns a different lesson. A communal spirit, ironically born through social distancing, causes people to turn outward, to neighbors both foreign and domestic. The election of November 2020 becomes a repudiation of America first politics. The nation pivots, as it did after World War II, from isolationism to international cooperation. Buoyed by steady investments and an influx of the brightest minds, the health-care workforce surges. Gen C kids write school essays about growing up to be epidemiologists. Public health becomes the centerpiece of foreign policy. The U.S. leads a new global partnership focused on solving challenges like pandemics and climate change.

In 2030, SARS-CoV-3 emerges from nowhere, and is brought to heel within a month.

Read more:
How the Pandemic Will End - The Atlantic

Read More...

UVM Researcher Offers Insights on Vaccines and COVID-19 – Seven Days

March 25th, 2020 9:44 pm

Sean Diehl likens the development of a new vaccine to the construction of a house. Before workers can turn a shovelful of dirt or hammer a nail, an architect must create a blueprint that shows how the building's thousands of components fit together and in what order.

Similarly, vaccine researchers trying to stop the spread of a deadly virus must start by mapping its messenger RNA. Decoding that genetic blueprint allows them to construct a safe and reliable vaccine that, they hope, will provide immunity for decades.

This time, researchers are racing to devise a vaccine that will stop a pandemic that's already upon us, using a never-before-tried method. It's akin to erecting a storm shelter using a new construction technique just as a Category 5 hurricane makes landfall.

Diehl is an assistant professor in the Department of Microbiology and Molecular Genetics at the University of Vermont's Larner College of Medicine. Since 2008, he's collaborated with the college's Vaccine Testing Center on projects involving infectious diseases, autoimmune disorders and vaccine development. In the past few years, Diehl's laboratory has focused on developing new protections against rotavirus, which is one of the most common and deadly causes of childhood diarrhea, and two mosquito-borne viruses dengue and Zika which infect tens of millions of people worldwide each year.

The 44-year-old Shelburne resident agreed to an interview with Seven Days months before the novel coronavirus made headlines. Since then, Diehl has joined the global effort to develop a vaccine against COVID-19.

On that front, researchers are already working at breakneck speed. They began in late December, when health authorities in Wuhan, China, first reported the outbreak of a viral pneumonia of unknown origin. On January 12, Chinese health authorities and the World Health Organization announced that they had mapped the entire sequence of the new coronavirus genome and shared it with researchers around the world.

On March 16, the National Institutes of Health announced the launch of a Phase 1 clinical trial to evaluate an experimental COVID-19 vaccine. In that study, being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, 45 healthy volunteers, ages 18 to 55, were injected with different doses of an experimental vaccine to evaluate its safety and efficacy in inducing immune responses.

Diehl is not involved in the Washington study. But, using the expertise he gained from researching dengue and Zika vaccines, he explained how a COVID-19 vaccine will be developed, how long it could last and how we can create more effective versions in the future.

"This is a brand-new approach," he said of the experimental coronavirus shot. "There is no current vaccine that's ever been developed this way."

How long before the public can be immunized? That's difficult to say. Diehl wouldn't offer a prediction beyond saying that "there are some aggressive timelines being talked about."

Ordinarily, vaccines involve years of research before human trials begin. But advanced genetic technologies and reductions in bureaucratic red tape could significantly shorten that timeline for COVID-19, with some estimates saying a vaccine could be available as early as this fall.

Several methods are used to create a vaccine, Diehl said. Under normal circumstances, the most common is to start with an attenuated, or weakened, version of a virus. Scientists inject this weaker version into laboratory animals, typically mice and nonhuman primates, hoping to trigger an immune response that doesn't make the animal sick. Only after long and rigorous study do vaccine developers request approval from the U.S. Food & Drug Administration to move on to human trials.

Consider the lengthy path that brought researchers to a vaccine for just one of four serotypes, or strains, of dengue (known as "Dengue 1, 2," etc.). Versions of the deadly virus are found in more than 100 countries around the world, posing a risk to about 40 percent of the world's population, or 3 billion people. According to the U.S. Centers for Disease Control and Prevention, as many as 400 million people are infected with dengue each year, of whom 100 million get sick and 22,000 die.

Though dengue's mortality rate is about 0.1 percent, comparable to seasonal flu, Diehl pointed out that its symptoms are much worse. "Dengue" may derive from the Spanish word for fastidious or careful, which describes the gait of a patient suffering from the disease.

The disease causes a very high fever that progresses into terrible joint, muscle and bone aches hence its nickname, "breakbone fever." Patients feel that their eyes are about to pop out of their heads.

Dengue is a particularly complicated disease to combat because of its four serotypes; an immunity to one offers no protection against the other three. If a person contracts Dengue 1 in, say, the Dominican Republic, they may recover without even knowing they were infected. However, if that person later travels to Puerto Rico and contracts Dengue 2, they have a greater chance of getting sick from the second exposure.

"For dengue," Diehl said, "it's taken, so far, 20 years and several billion dollars to get to the point of [having] the one vaccine that's on the market right now, for a very limited use."

What does this mean to researchers racing for a coronavirus vaccine? Speaking in "really broad brushstrokes," Diehl said, the way genetic material is encoded in the coronavirus is "very similar" to the coding of dengue. Both viruses have one long, continuous string of nucleic acid, or mRNA, that is "read" as a series of letters representing its chemical components: adenine (A), guanine (G), cytosine (C) and thymine (T).

In the case of dengue, that string is 10,000 letters long. In COVID-19, Diehl said, it's 25,000.

Working with a much longer string of information naturally presents more challenges. But, Diehl said, COVID-19 researchers don't need a full understanding of how all 25,000 letters of the genome function. The novel approach they're using to develop a vaccine is focused on the 3,000 to 5,000 letters that they believe may induce an early protective immune response. If they can pinpoint those letters, they will, in effect, buy themselves more time.

By now, most people who are following news of the unfolding pandemic have seen images of the COVID-19 virus, which resembles a fuzzy tennis ball riddled with darts or crowns. Those darts, which are called spike proteins, enable the virus to attach itself to a target cell, pass along its genetic material and reproduce.

A vaccine is essentially useless, Diehl said, if it triggers an immune response "post-fusion," or after the virus binds to the cell. The aim of this experimental vaccine is to induce an immune response before fusion happens.

"If we can block that," he said, "the virus has nowhere to go, and it dies."

The good news: Vaccine developers now have machines that can rapidly synthesize and mass produce the crucial 3,000- to 5,000-letter sequences that can be used to induce a pre-fusion immune response.

The bad news: That immune response won't last for long, because the mRNA used to produce it is an unstable molecule that degrades quickly in the body. "A good vaccine will last decades. This is probably single years," Diehl said.

That may be enough, though. Here's where Diehl joins the global effort: He has submitted a protocol seeking permission to collect and study blood samples from patients who have recovered from COVID-19. Once researchers better understand how all 25,000 nucleotides work together, he said, they can move on to developing vaccine "versions 2.0, 3.0 and beyond" that will induce "immune memory."

It's no surprise that Diehl uses construction metaphors to describe the microscopic workings of cells and viruses; his father, who's now retired, worked for years in construction. To his mother, a nurse, Diehl attributes his desire to work in a public health field and help others.

A native of Rome, N.Y., Diehl earned a bachelor's degree in chemistry at the State University of New York Geneseo. There, he developed an interest in immunology, and a professor suggested he pursue a doctoral degree. The first member of his family to attend a four-year college, Diehl hadn't known until then that students could get funding to pursue graduate degrees.

Earning his PhD at UVM, Diehl met his now-wife, Sandra. When he completed the degree, they moved to the Netherlands, where Sandra was born and raised.

After spending 2003 to 2008 at the University of Amsterdam, Diehl returned to Vermont and joined the faculty at UVM, where he's been ever since. Sandra works as a pediatric nurse at the UVM Medical Center. The couple has two daughters, Jill, 11, and Vera, 9.

Diehl admitted that it's frustrating to see vaccines demonized by the public when he knows how much "blood, sweat and tears" go into making them. He sees them as a "miracle product" that saves lives. "And then some people just choose not to believe in them."

What keeps him interested in immunology?

"The fact that we'll never figure it all out," he said. Unlike the study of many processes in the human body, such as the cardiopulmonary system, immunology is constantly evolving and discovering new cell types. And those discoveries almost always have real-world health applications, whether it's combating an autoimmune disorder or working to end a global pandemic. Given its complexity, COVID-19 could keep researchers busy for years to come.

"At the root of it," Diehl said, "I always know that there's so much still to be learned."

Link:
UVM Researcher Offers Insights on Vaccines and COVID-19 - Seven Days

Read More...

MSU scientists put the heat on microbes – MSUToday

March 25th, 2020 9:44 pm

Hurricanes, floods, drought and fire. Extreme weather events are becoming more frequent as the climate changes and can destroy entire landscapes both visible and invisible.

Like humans, microbes need disaster response strategies that facilitate the rescue and recovery of their ecologically crucial communities.

But what do microscopic rescue efforts look like, and can humans help?

In a new study, published in a special issue of Philosophical Transactions of the Royal Society B, researchers in the lab of Michigan State University microbial ecologist Ashley Shade put microbes under extreme heat to find out.

We know microbes provide crucial functions for maintaining the health of their ecosystems they cycle nutrients, carbon and have important feedback with climate change processes, said Shade, an assistant professor in MSU College of Natural Sciences Department of Microbiology and Molecular Genetics, whose research is supported by an National Science Foundation Early CAREER Award. We want to get a good handle on how their function might change by exploring how quickly microbes recover after the change takes place, and what we might we be able to do to manage them back to stability.

Between 20% and 80% of all microbes in the environment exist in a dormant state, like microbial sleeping beauties waiting for the right moment to wake up and function. In fact, dormancy is a widespread, bet-hedging strategy against famine and other suboptimal conditions that has evolved separately along every major branch of life. Some microbes can exist in this suspended, but viable, state for thousands of years.

We know that there are ways microbes recover after a disturbance by replenishing their populations through dispersal through air and water, Shade said. What is special about this study is that we looked at the contributions of dormant microbes as well.

Using sterilized canning jars filled with soil and their microbial communities, Shade and graduate student Jackson Sorensen designed three separate treatments.

The control received no treatment, but the second and third treatments were cooked to a sweltering 60 degrees Celsius the temperature of an underground coal fire in Centralia, Pennsylvania that Shade has been studying for six years. After cooling, the second treatment was given dispersed cells from the control jars to boost recovery.

We reproduced what would happen in the environment after a disturbance where dispersal is most likely from the next neighborhood over, Shade said. We used just a tiny bit of it, not comprising a substantial volume, and the microbes grew after the disturbance subsided, showing a little dispersal can go a long way.

The third treatment was denied outside assistance. Instead, Shade and her team watched the jars to see what role dormant microbes played in returning the microbial community to a healthy, stable state.

What we found was that both reactivation and dispersal contributed to how microbes respond to the extreme event, Shade said. This is an important finding because it suggests that it is not just outside cells rescuing the population but also dormant microbes in the disturbed environment that reactivate and support recovery.

The nearly yearlong experiment was not long enough to see the communities of microbes fully recover, even with the combined tools of dormant reactivation and outside dispersal. Still, Shade found value in what she describes as dormancy dynamics.

This experiment gives us another strategy to manage microbial communities, she said. Think about taking antibiotics for an ear infection that, as a side effect, kills beneficial microbes in the gut. Dispersal might be analogous to eating yogurt to recover those beneficial microbial functions, but another strategy could be to encourage the already existing, viable gut microbes to wake up and contribute to healthy functionality.

Rousing dormant microbes and understanding why they go into dormancy is an area of active research.

Controlling dispersal in the environment is hard, Shade said. Microbes can travel through water, the air, on insects and inside insect guts and by hitchhiking on other animals as well. But controlling when microbes wake up and go to sleep could be another interesting strategy for managing them to support a healthy environment as we face a changing climate. One day, we may be able to wake up local microbes to help environments recover even faster after extreme events.

Visit link:
MSU scientists put the heat on microbes - MSUToday

Read More...

Twelve Women Who Have Shaped The History of the BioHealth Capital Region – BioBuzz

March 25th, 2020 9:44 pm

The BioHealth Capital Region (BHCR) and its life science ecosystem have a rich and deep history of pioneering scientific innovation, research, development, and commercialization. The regions history has been written by life science anchor companies, scientific research universities, government research organizations, rich startup culture, and serial entrepreneurs, all of whom have played critical roles in transforming the BHCR into one of the most innovative and productive biocluster in the world.

Contributions to the BHCRs legacy of life science achievement have emerged from all staffing levels, various labs, countless executive teams, numerous entrepreneurs and biohub support organizations. Contributions have arisen from an intricate tapestry of backgrounds and cultures.

Women, in particular, have had a strong hand in shaping the history of the BHCR. In celebration of Womens History Month, were taking a closer look at the achievements of female life science leaders that have laid the groundwork for the next generation of women trailblazers in the BHCR and made the region what it is today.

Dr. Fraser is one of the most influential figures in BHCR history. In 1995, she was the first to map the complete genetic code of a free-living organism while at the Institute for Genomic Research (TIGR) in Rockville, Maryland. It was there that the automation of the DNA sequencing process made the idea of large-scale sequencing efforts tangible. As President and Director of TIGR, Fraser and her team gained worldwide public notoriety for its involvement in the Human Genome Project, which was completed in 2000 with the presentation of a working draft of the fully sequenced human genome.

As a leader, Fraser provided her researchers with the infrastructure to collaborate and apply multi-disciplinary team science and empowered them to think big. She is also most importantly known for how she challenged her team to ask the right questions, which is the root of scientific progress and success.

Her work at TIGR and as part of the Human Genome Project are foundational events in the regions history, as it marked the BHCR as the epicenter of genomic research and helped spark the regions biotech boom. In fact, it was a controversial partnership with TIGR that gave Human Genome Sciences(HGSi) the first opportunity to utilize any sequences emerging from TIGR labs. The mass of genetic information and sequences, especially that associated with diseases, that HGSi acquired catapulted them into biotech history and an important anchor company within the region.

Dr. Fraser is widely viewed as a pioneer and global leader in genomic medicine; she has published approximately 320 scientific publications and edited three books; she is also one of the most widely cited microbiology experts in the world. She founded the Institute for Genome Sciences at the University of Maryland in 1997. The institute currently holds 25 percent of the funding thats been awarded by the Human Microbiome Project and has been referred to as The Big House in genetics.

Dr. Judy Britz is yet another female life science pioneer that put the BHCR on the map. While working as a research scientist at Electro-Nucleonics Inc., Dr. Britz developed one of the first licensed blood screening tests for HIV, and launching a storied career that has spanned approximately 25 years. She is also a serial entrepreneur that has successfully raised $50M in capital and served as the top executive for two highly successful Maryland-located companies.

Dr. Britz was the first woman to lead the states biotech initiative as the first announced Executive Director of the Maryland Biotech Center. The center was launched under the Maryland Department of Commerce to deploy a strategic life science economic development plan under Governor Martin OMalleys $1.3B, 2020 Vision and to be a one-stop-shop and information center to promote and support biotechnology innovation and entrepreneurship in Maryland.

Judy was the first woman to lead Marylands life sciences initiative, bringing industry experience and perspective to the states economic development activities, a focus still maintained under Governor Hogans leadership today, shared Judy Costello, Managing Director, Economic Development BioHealth Innovation, Inc., who served as Deputy Director under Dr. Britz.

Much of the work done by Dr. Britz and her team laid the foundation and seeded the commercialization efforts that have blossomed into the thriving #4 Biotech Hub that we have today.

GeneDx was founded by Dr. Bale and Dr. John Compton in 2000. The company recently celebrated its 20th anniversary. Since its founding, GeneDx has become a global leader in genomics and patient testing. Under her leadership, the Gaithersburg, Maryland company has played an important role in the history of genetic sequencing and the rise of the BHCR as a global biohealth cluster.

GeneDx was the very first company to commercially offer NGS (Next Generation Sequencing) testing in a CLIA (Clinical Laboratory Improvement Amendments) lab and has been at the leading edge of genetic sequencing and testing for two decades. The companys whole exome sequencing program and comprehensive testing capabilities are world-renowned.

Prior to launching GeneDx, Dr. Bale spent 16 years at NIH, the last nine as Head of the Genetic Studies Section in the Laboratory of Skin Biology. She has been a pioneer during her storied career, publishing over 140 papers, chapters and books in the field. Her 35-year career includes deep experience in clinical, cytogenetic, and molecular genetics research.

Prior to being named CEO and Chair of the Board of Sequella in 1999, Dr. Nacy was the Chief Science Officer and an Executive VP at EntreMed, Inc. EntreMed was one of the most influential BHCR companies in the 1990s. EntreMed, MedImmune, Human Genome Sciences and Celera Genomics all played critical roles in creating the globally recognized, top biocluster that the BHCR has become.

After earning her Ph.D. in biology/microbiology from Catholic University, Nacy did her postdoc work at the Walter Reed Army Institute of Research in the Department of Rickettsial Diseases; her postdoc performance earned a full-time position at Walter Reed that started a 17-year career at the institute. After a highly successful run, Nacy left Walter Reed to join EntreMed.

Today, Dr. Nacy leads Rockville, Marylands Sequella, a clinical-stage pharmaceutical company focused on developing better antibiotics to fight drug-resistant bacterial, fungal and parasitic infections. Sequellas pipeline of small molecule infectious disease treatments have the potential to improve the treatment and outcomes for the over 3 billion people worldwide that are impacted by increasingly drug-resistant infectious diseases.

Emmes Corporation is the largest woman-led organization in the BHCR and is headed by Dr. Lindblad, who started her career at Emmes in 1982 as a biostatistician. She has been with Emmes for nearly 40 years, ascending to become VP in 1992, Executive VP in 2006 and ultimately the companys CEO in late summer of 2013.

Dr. Lindblad has published more than 100 publications and presentations has served as a reviewer of grant and contract applications for the National Institutes of Health (NIH) and has chaired or served on Safety and Data Monitoring Committees across multiple disease areas. Emmes is a life science anchor company for the BHCR, employing more than 600 staff globally with its headquarters in Rockville, Maryland.

Under Kings leadership, GlycoMimetics (GMI), an oncology-focused biotech, went public, secured an exclusive global licensing agreement with Pfizer and was instrumental in raising significant amounts of capital for the company. She was also the first woman Chair of Biotechnology Innovation Associations (BIO, 2013-14), where she still plays an active role on BIOs Executive Committee.

A graduate of Dartmouth College and Harvard Business School, King has had a celebrated career in both biopharma and finance. Prior to becoming CEO of GMI, King served as an Executive in Residence for New Enterprise Associates (NEA), one of the leading venture capital firms in the U.S. She has also held the position of Senior Vice President of Novartis-Corporation. King joined Novartis after a remarkable ten year run with Genetic Therapy, Inc. where she was named CEO after helping Genetic Therapy navigate the organization through various growth stages, including the companys sale to Novartis. King was named the Maryland Tech Councils Executive of the Year in 2013, the Top 10 Women in Biotech by FierceBio and has served on multiple boards across her career.

Dr. Connolly has had a pioneering career in the life sciences. She was the very first woman to graduate from Johns Hopkins Universitys Biomedical Engineering Doctoral Program in 1980. She was also a member of the first female undergraduate class entering Stevens Institute of Technology in 1971.

For decades, Dr. Connolly tirelessly worked to build up what is now known as the BHCR. In 1997, shortly before the region gained wider recognition as a biotech hub, she was the first person to be designated the state of Marylands biotechnology representative. Dr. Connollys career has spanned academia, government, and industry, including co-founding a startup and working as the Business Development Director for EntreMed, Inc., an original BHCR anchor company. She is the former Director of Maryland Industrial Partnerships Program (MIPS) and was inducted into the College of Fellows by the American Institute for Medical and Biological Engineering (AIMBE) in 2013.

Dr. Kirschstein played an enormous role in shaping the BHCR as NIH Deputy Director from 1993 to 1999 during the regions early formative years. She also served as Acting Director of NIH in 1993 and from 2000 to 2002. A pathologist by training, she received her medical degree from Tulane University in 1951 and went on to a long, successful career at the Division of Biologics Standards that lasted from 1957 to 1972.

While at the Division of Biologics Standards, Dr. Kirschstein played an important role in testing the safety of viral vaccines and helped select the Sabin polio vaccine for public use. She eventually ascended to Deputy Director of the group in 1972 and was later appointed the Deputy Associate Commissioner for Science at the FDA. In 1974 she became the Director of the National Institute of Medical Sciences at NIH and served in that role for 19 years.

Her awards and accolades are too numerous to list, but one notable honor came in 2000 when she received the Albert B. Sabin Heroes of Science Award from the Americans for Medical Progress Education Foundation.

Lastly, we want to recognize four additional women for their contributions to launching an organization that has impacted thousands of women by promoting careers, leadership, and entrepreneurship for women in the life sciences Women In Bio.

Women In Bio (WIB), one of the most important and influential support organizations for women in the life sciences, was founded in 2002 to help women entrepreneurs and executives in the Baltimore-Washington-Northern Virginia area build successful bioscience-related businesses. WIB started as a BHCR organization but has expanded its footprint to 13 chapters across the U.S. with 225 volunteer leaders and 2,600 members. The non-profit group has created a forum for female life science entrepreneurs and executives based on its core philosophy of women helping women.

WIB founders are Anne Mathias, a local venture capitalist and current Senior Strategist with Vanguard;

Elizabeth Gray, co-founder of Gabriel Pharma and current Partner at Willkie Farr & Gallagher LLP;

Robbie Melton, former Director of Entrepreneurial Innovation at TEDCO and current Director of Kauai County, Hawaiis Office of Economic Development;

and Cynthia W. Hu, COO, and General Counsel at CASI Pharmaceuticals.

In conclusion, we can not fairly capture the true history of life science and the BioHealth Capital Region without giving special recognition to Henrietta Lacks. In 1951 a Johns Hopkins researcher created the first immortal human cell line from cervical cancer cells taken from Lacks. That cell line, known as HeLa, is the oldest and most commonly used human cell line which was essential in developing the polio vaccine and has been used in scientific landmarks such as cloning, gene mapping and in vitro fertilization.

Though she was a black tobacco farmer from southern Virginia, her impact on science and medicine is unquestionable. She never knew that the Doctor took a piece of her tumor that would be used by scientists who had been trying to grow tissues in culture for decades without success. For some reason, that is still unknown, but her cells never died and the first immortal human cell line was born.

Thank you to all of the women who have been so influential in shaping the field of science, the industry of biotechnology and the BioHealth Capital Region.

Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.

Originally posted here:
Twelve Women Who Have Shaped The History of the BioHealth Capital Region - BioBuzz

Read More...

Research interrupted: Lab groups find their way together – Cornell Chronicle

March 25th, 2020 9:44 pm

When Mariana Wolfner, a Cornell geneticist and molecular biologist,learned March 15she needed to suspend all noncritical research as part of the universitys effort to stem thecoronavirus outbreak, she had two main concerns.

The first was how best to help her students.

Everyone is just stunned ..., obviously because of the coronavirus, but also because of their research suddenly stopping or slowing down, said Wolfner,the Goldwin Smith Professor of Molecular Biology and Genetics in the College of Arts and Sciences (A&S). She has emphasized staying in contact with her lab virtually, to create a sense of community and support.

Ciro Cordeiro, a postdoc in Scott Emrs lab in Weill Hall, organizes frozen cell samples.

The other thing thats been hard has been trying to figure out what to shut down without forgetting something critical to maintain, said Wolfner, a Stephen H. Weiss Presidential Fellow.

She and other researchers on campus have found that people are making extra efforts to help each other.

Everyone is working together, pitching in to find solutions to problems as they arise, saidScott Emr,the Frank Rhodes Professor of Molecular Biology and Genetics in A&S and director of the Weill Institute for Cell and Molecular Biology. The atmosphere in the lab is very collegial and supportive.

With universities across the country also suspending research, scientists have offered transition strategies on social media. Students in Wolfners lab also consulted friends at other institutions.

Using that, weve come up with a plan, Wolfner said. Her students canvassed lab members to determine what experiments were absolutely critical. A postdoctoral researcher made a shift schedule for the lab.

Laura Harrington, a professor of entomology whose research seeks to understand mosquito biology and use that knowledge to prevent them from spreading disease, has noticed small but meaningful acts of kindness. Students have made their own hand sanitizer and made it available. Entomology graduate students circulated a list of people willing to provide a room in their homes for students who had no place to go.

I was really touched by people reaching out, she said.

Another major consideration for researchers has been what to do with stocks of animals or cultures that are invaluable for their research.

Avery August, professor of immunology and vice provost for academic affairs, said maintaining animal models used in his lab will be essential for when lab members return to work.

We work a lot with animals, he said, adding that animals used in research can take months and even years to develop. Along with maintenance, research animals must continue to be bred. A lab member will come in regularly to make sure the animals are cared for, so that we dont lose six to nine months if we just stopped everything, August said.

Harrington and her lab colleagues are in a race to complete an essential research project theyve been working on for the last two years, on the acoustic behavior of disease-carrying Anopheles mosquitoes, a key for understanding how males hone in on females for mating. Weve got a whole bunch of really valuable mosquito strains that we need to maintain, she said.

Wolfners lab does pioneering work with fruit flies, which must be maintained and bred. One students entire doctoral thesis is based on a strain of flies the student created. To keep all the flies alive, a team is working at the lab in shifts, so theres only one person in the lab at a time.

Perhaps the biggest task for faculty has been supporting and guiding students during this transition.

A lot of people are upset, said Colin Parrish, the John M. Olin Professor of Virology at the Baker Institute for Animal Health. The students are trying to figure out what theyre going to do to finish their research projects, finish their theses.

Postdocs in Scott Emr's lab in Weill Hall work to freeze down cell samples to preserve the labs research.

Parrish has been helping his students come up with solutions ways they can be productive remotely, read papers and write. One of his students who was scheduled to travel for a job interview will now be interviewing online.

Its been especially hard for senior undergraduate students, because they are graduating, Harrington said.

One of her seniors was upset she was not able to finish her honors project research. I just told her, Youve done the best you can with the lab work, but it really is the experience that is the educational component rather than the end product, Harrington said.

Emrs group held a pre-graduation ceremony and celebration March 17, complete with a decorated sheet cake with an inscription, for two graduating seniors who feared they wouldnt have a graduation ceremony.

A one-hour pause in our day that made us all feel good, Emr said, especially the two seniors in my lab who are likely saying a final goodbye to Cornell when they leave Ithaca in the next three days.

As people leave campus, most lab groups have plans to stay in touch via regular Zoom meetings. Wolfners group has already held a Zoom lab meeting where they discussed a journal article just to do something normal, and it made us relax, she said. They plan to meet virtually three times a week.

Harringtons lab had its first virtual meeting on March 16. We tried to laugh about things, you know, talk to each other and share ideas, support each other, she said.

As a community, everyones done a great job, Parrish said. People are doing what they can to make it a smooth transition, and hopefully, in a month or two, when things settle down, well be able to start moving things in the other direction.

Research and lab work are being scaled down across Cornell Universitys campus to stem the spread of COVID-19. In Scott Emrs molecular biology and genetics lab, postdoctoral associates are putting most research on ice.

Read the rest here:
Research interrupted: Lab groups find their way together - Cornell Chronicle

Read More...

Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis – P&T…

March 25th, 2020 9:44 pm

NEW YORK, March 25, 2020 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfolio of programs and the company's first clinical trials, further establishing its leadership in the gut-brain axis field.

All investors from the Series B financing participated in the Series C round, including The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments, and Bill Gates. New investors include Casdin Capital, Greenspring Associates, and two unnamed leading institutional investors.

"Four years ago, we started our journey to build a preeminent biotech based in New York City as a first-mover in the gut-brain axis space. Now, this Series C financing will enable us to advance multiple programs to clinical development," said Kallyope CEO Nancy Thornberry.

The Series C financing comes after four highly productive years in which Kallyope has built a portfolio of programs directed to novel targets in a wide array of diseases. In support of these programs, the company has established industry-leading capabilities in designing oral small-molecule drugs that selectively target the gut but not the rest of the body.

The company today also announced its lead program targeting satiety circuits for weight loss, with clinical testing expected to begin later this year. A second program targeting gut barrier function with potential relevance for inflammatory bowel disease (IBD) and several other diseases is anticipated to enter the clinic soon after. In addition, the company continues to advance a broad portfolio of programs for gastrointestinal, CNS, and inflammatory disorders.

"Kallyope pursues programs where the company's platform provides an edge over other approaches and where we have an opportunity to deliver major clinical benefits rather than incremental improvements over current treatments. We are targeting neural and hormonal circuits, including novel vagal circuits, involved in a broad array of physiology and disease," said Thornberry.

"Kallyope has made significant progress since the company's inception in late 2015. Its platform is enabling a mechanistic understanding of the gut-brain axis, which in turn has revealed new, actionable biology that the company is now exploring in several promising programs. I believe that Kallyope's platform and rigorous approach to identifying, characterizing, and targeting gut-brain circuits with gut-restricted small molecules has greatly increased its odds of success in clinical studies," said Kallyope co-founder and board member Tom Maniatis, Ph.D.

About Kallyope Inc.

Kallyope, headquartered at the Alexandria Centerfor Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information visitwww.kallyope.com.

Contact

Morgan Warners (202) 337-0808mwarners@gpg.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/kallyope-inc-announces-112m-series-c-financing-to-support-first-clinical-trials-and-advance-portfolio-of-programs-targeting-the-gut-brain-axis-301029250.html

SOURCE Kallyope Inc.

See more here:
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis - P&T...

Read More...

The Harvard Wyss Institute’s response to COVID-19: beating back the coronavirus – PRNewswire

March 25th, 2020 9:44 pm

Essentially all medical treatment centers impacted by SARS-CoV2 (CoV2), the SARS-family virus that causes COVID-19, are overstrained or unable to confront the virus, starting from their ability to diagnose the virus' presence in the human body, treat all infected individuals, or prevent its spread among those that have not been infected yet. Therefore, finding better solutions to diagnose, treat, and prevent the disease, is key to combating this menace and bringing this pandemic under control. Equally concerning, there are worldwide shortages on the front lines in hospitals in our region and around the world, including rapidly depleting supplies of personal protective equipment, such as N95 face masks, and nasopharyngeal swabs needed for COVID-19 diagnostic testing. Solving these challenges requires rapid responses and creative solutions.

"With our highly multi-disciplinary and translation-focused organization, we [the Wyss Institute] were able to quickly pivot, and refocus our unique engineering capabilities on much needed diagnostic, therapeutic, and vaccine solutions, and we hope to be part of the solution for many of the innumerable problems the present pandemic poses," said Wyss Institute Founding Director Donald Ingber,M.D., Ph.D., who also is theJudah Folkman Professor of Vascular Biologyat Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). "We strive to make a major contribution to bringing this crisis under control, and are confident that what we accomplish under duress now will help prevent future epidemics."

Meeting challenges on the front lines of patient care

Many of the Institute's hospital partner institutions and government agencies have reached out to Institute leadership to assist in this rapidly escalating battle against COVID-19. Ingber's team is working closely with collaborators at Beth Israel Deaconess Medical Center(BIDMC), other Harvard-affiliated hospitals, and generous corporate partners to develop potential solutions to the increasing shortage of nasopharyngeal swabs and N95 face masks. Senior Staff Engineers Richard Novak, Ph.D., and Adama Sesay, Ph.D., and Senior Research Scientist Pawan Jolly, Ph.D., are working diligently with our clinical partners to help devise a solution as quickly as possible.

Diagnosing COVID-19 more quickly, easily, and broadly

With COVID-19 rapidly spreading around the planet, the efficient detection of the CoV2 virus is pivotal to isolate infected individuals as early as possible, support them in whatever way possible, and thus prevent the further uncontrolled spread of the disease. Currently, the most-performed tests are detecting snippets of the virus' genetic material, its RNA, by amplifying them with a technique known as "polymerase chain reaction" (PCR) from nasopharyngeal swabs taken from individuals' noses and throats.

The tests, however, have severe limitations that stand in the way of effectively deciding whether people in the wider communities are infected or not. Although PCR-based tests can detect the virus's RNA early on in the disease, test kits are only available for a fraction of people that need to be tested, and they require trained health care workers, specialized laboratory equipment, and significant time to be performed. In addition, health care workers that are carrying out testing are especially prone to being infected by CoV2. To shorten patient-specific and community-wide response times, Wyss Institute researchers are taking different parallel approaches:

Advancing antiviral therapeutics on the fast track

To date there is no antiviral drug that has been proven to reduce the intensity and duration of the infection in more seriously affected patients, or protect vulnerable patients from CoV2 infection. Doctors can merely provide supportive care to their COVID-19 patients by making sure they receive enough oxygen, managing their fever, and generally supporting their immune systems to buy them time to fight the infection themselves. Research groups in academia and industry working at breakneck pace by now have compiled a list of candidate therapeutics and vaccines to could offer some help. However, given the high failure rates of candidate drugs in clinical trials, more efforts are needed to develop effective medicines for a world population that likely will vary with regards to their susceptibility and access to new therapeutic technologies.

The ongoing COVID-19 pandemic requires rapid action, and the fastest way to combat this challenge is by repurposing existing drugs that are already FDA approved for other medical applications as COVID-19 therapeutics. While clinicians around the world are attempting to do this, the approaches have been haphazard, and there is a great need to attack this problem in a systematic way.

In search of ultimate protection a vaccine

With no vaccine currently available, but several vaccine candidates being explored around the world, Wyss Institute researchers led by Wyss Core Faculty member David Mooney,Ph.D., are developing a material that could make vaccinations more effective. Previously, Mooney's team has developed implantable and injectable cancer vaccinesthat can induce the immune system to attack and destroy cancer cells.

Understanding how COVID-19 develops and how to control it

COVID-19 does not strike equally strong in every individual that it infects. Independent of age, some are prone to become seriously ill, while others show an astonishing level of resilience against the disease. Figuring out the biological basis for these differences could lead to new protective strategies.

On the national level, Walt is a member of a COVID-19 discussion started at the National Academies' newly formed "Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats." The committee is strongly focusing now on the present coronavirus pandemic to find ways to help the federal government consolidate and streamline efforts across the nation but will also work long-term to develop strategies and make recommendations for future health threats.

At the international level, the Wyss Institute functions as a Center of Excellence of the Global Virus Network(GVN), with Ingber as leader and the other Wyss Faculty as key participating members. The GVN is designed to integrate surveillance and response efforts for biothreats, epidemics, and pandemics by integrating efforts of top virus research institutions from around the world.Ingber is also currently working closely with the Defense Advanced Research Projects Agency(DARPA) and Bill & Melinda Gates Foundation, as well as in active discussions with the NIH's National Institute of Allergy and Infectious Diseases(NIAID), Biomedical Advanced Research and Development Authority(BARDA), and Public Health England, as they all try to align and coordinate efforts to meet this monumental health challenge.

"The Wyss Institute and its collaborators are taking exactly the type of comprehensive, integrated approach to addressing this pandemic that is required at local, national, and international levels," said Walt.

PRESS CONTACTS

Wyss Institute for Biologically Inspired Engineering at Harvard UniversityBenjamin Boettner,[emailprotected], +1917-913-8051

The Wyss Institute for Biologically Inspired Engineering at Harvard University(http://wyss.harvard.edu) uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard's Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, DanaFarber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charit Universittsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.

SOURCE Wyss Institute for Biologically Inspired Engineering at Harvard University

Home

Visit link:
The Harvard Wyss Institute's response to COVID-19: beating back the coronavirus - PRNewswire

Read More...

Understanding Holistic Care in Relation to Chronic Illness – Patch.com

March 25th, 2020 7:45 am

This post was contributed by a community member. The views expressed here are the author's own.

Article content first published on DrGregoryBurzynski.com

-

In my recent blog post "Understanding Approaches for Pain Management and Patient Care" I speak on the lasting effects of holistic health care and the benefits that it has in terms of managing pain and taking care of the "whole" patient.Before I get started, it is important to mention that the holistic approach to health does not reject conventional medicine, but is a sensible, complete form of healing that considers your child's entire picture of health and uses the best and most appropriate options for healing. It is a process of strengthening every system of the mind-body and allowing your child's natural healing potential to flourish.Many of the chronic health problems that affect children will respond best when addressed from a holistic point of view.

Conventional v.s Alternative Medicine

The views expressed in this post are the author's own. Want to post on Patch? Register for a user account.

View original post here:
Understanding Holistic Care in Relation to Chronic Illness - Patch.com

Read More...

Finding a Peaceful Place: Is Now the Time to Try Meditation? – TAPinto.net

March 25th, 2020 7:45 am

Is Now the Time to Try Meditation?

As many of us hunker down in our homes at this frightening and stressful time, there are all kinds of things we are doing to fill the time. Some things we havent done in a while, like the 1000 piece puzzle that is near completion. Other things are brand new, like using Duolingo to learn a foreign language. How about trying out meditation? The science is clear, meditation is a quick way to reduce stress, something we could all use. For those who havent tried before, it can take a little time to get started, so how about now?

When my husband, Nez, was being treated at Memorial Sloan Kettering Cancer Center (MSKCC) a few years ago, our stress and anxiety was at an all-time high. This is when we both began a meditation practice. We used a free 21-day series by Oprah Winfrey and Deepak Chopra to get started. A new series was just released yesterday #HopeGoesGlobal. You register online and can access the free meditations on your computer, or you can download the app on your phone or iPad. Oprah and Deepak give inspirational thoughts and then there is roughly 15 minutesof meditation.

Sign Up for Holmdel & Colts Neck Newsletter

Our newsletter delivers the local news that you can trust.

You have successfully signed up for the TAPinto Holmdel & Colts Neck Newsletter.

There are other choices of course. If you Google free meditation you will get over 400,000 results. MSKCC has a series online as part of their Integrative Medicine. The App Stores have all kinds of offerings, such as Headspace or Calm. You can find meditation on many fitness apps like Peloton, and YouTube is a treasure trove. Find something that speaks to you, find a quiet corner, get comfortable, and get started. Help clear and calm your mind; even if only for a few minutes.

Emily & Nez Nikoo

After meeting at Purdue University, Emily & Nez Nikoo (both Electrical Engineers), married and began their professional journey working together first for the space program and then in media & entertainment. After tackling lifes challenges, Emily gravitated to healthcare innovation and Nez to STEM advocacy and education.

See more here:
Finding a Peaceful Place: Is Now the Time to Try Meditation? - TAPinto.net

Read More...

Expert answers: can cannabis and CBD affect coronavirus? – Health Europa

March 25th, 2020 7:45 am

The biggest question Im getting asked is around how CBD and medical cannabis may affect contracting or recovering from coronavirus, and about what else we can do to stay well.

People are asking if cannabis and CBD can help buffer the immune system against getting COVID-19 in the first place, and if you do get it, can CBD and cannabis help treat it? What about the possibility that NSAID anti-inflammatory drugs may have a negative effect on the virus once you are infected and wait a minute CBD is an anti-inflammatory too, so what does that mean for CBD?

These are all valid questions and so far, even in terms of the anti-inflammatory drugs and the effect on corona, it is still unclear what the relationship is, if there is one. Many doctors are still recommending sticking to Acetaminophen for the fever for now and avoiding NSAID over the counter drugs until we know more.

As for CBD and cannabis, we dont have any studies showing it has any effect on the coronavirus, although there are some interesting studies on medical cannabis and smoked cannabis use and HIV progression.

On Facebook and social media, many CBD and cannabis advocates are claiming that they boosted their immunity successfully against all viruses using the plant, and recommending others do the same.

As both a cannabis specialist and doctor trained in natural medicine and western medicine, it is important to let people know the facts and be totally honest about what we dont know. Its also critical not to make false claims when we are all understandably a bit scared, and of course want to do everything we can to protect ourselves and our loved ones.

The miracle cure claims that some members of the natural wellness community can sometimes make, even when well-intentioned, can have harmful effects on peoples behaviour and also tarnish the industry as promoting snake oils.

This effect can distance our more conventional medicine and research colleagues who are not well versed in botanical medicine, and hurt the progress plant medicine has made in recent years in gaining support and credibility through academic research and inquiry, partnering with the research and those physicians open-minded enough to consider them.

Plant medicines like CBD and medical cannabis do so many amazing things that there is no need to stretch the truth or make claims that cannot be backed up, at least not currently.

Probably the best way we can support our immunity is avoiding alcohol, staying active while we stay home (dance parties in the living room anyone?) and taking up a simple relaxation or meditation practice to decrease stress hormones.

If you are into supplementing, you could consider adding some adaptogen mushrooms, along with liposomal glutathione (not a direct immune boost but may help support the liver).

Eating a diet rich in micronutrients, zinc, vitamin C, flavonoids like quercetin (in both cannabis and apples) and getting good sleep are all good things to start now if you havent already.

Melatonin, our sleep hormone made while we sleep can help healthy immune function too. Deep breathing practices and laughter may also have a positive effect on our immune systems too. So, you can feel like you have done something by putting on a funny film and having a good deep belly laugh to get those lungs working while you self-isolate.

Even if you do everything right you may still end up getting coronavirus, but the good news is that most people not in high risk groups will have a mild illness course and recoup at home. Some carriers may not even have any symptoms at all or even know they had it, which is why social distancing is so important, since asymptomatic transmission rates are thought to be quite high with coronavirus.

Dr Dani Gordon MD, CCFP, ABOIM, ABIHMGuest AuthorUK Cannabis Medicine Specialist US Integrative Medicine Consulting & Training for Physicians

Do you want the latest news and updates from Medical Cannabis Network? Click here for your free subscription, and stay connected with us here.

Go here to read the rest:
Expert answers: can cannabis and CBD affect coronavirus? - Health Europa

Read More...

Page 640«..1020..639640641642..650660..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick